Carboplatin 790mg/500ml in Glucose 5% infusion bags
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Carboplatin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Carboplatin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Clinical guidelines and formulary information
British National Formulary
Carboplatin
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(13)
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer (TA1092)
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)
Ovarian cancer: recognition and initial management (CG122)
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
204 found
Half-life
1.1-2 hours
Mechanism
Carboplatin predominantly acts by attaching alkyl groups to the nucleotides, lea…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
75 mg/m
[L32253]…
Half-life
1.1-2 hours
[L32253]
Protein binding
40%
[A230463]
However, the free platinum is 40% irreversibly bound to plasma proteins.
[A230458]
Volume of distribution
30 minute
[L32253]
Metabolism
[A230158][A230473]
Elimination
65%
[A230463][L32253]…
Clearance
30 minute
[L32253]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Carboplatin was granted FDA approval on 3 March 1989.[L32248]
[L32253]
Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
[L32253]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1188 interactions
[A230478][L32253]
Treat patients with symptomatic and supportive measures, which may include delaying their next treatment.
[A230478]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L32253]
A 75 mg/m2 dose reaches a Cmax of 9.06 ± 0.74 µg/mL, with an AUC of 27.18 ± 11.28 h\*µg/mL.
[A230463][L32253]
A 450 mg/m2 dose reaches a Cmax of 55.39 ± 18.30 µg/mL, with an AUC of 224.41 ± 69.07 h\*µg/mL.
[A230463][L32253]
[L32253]
[A230463]
However, the free platinum is 40% irreversibly bound to plasma proteins.
[A230458]
[L32253]
[A230158][A230473]
[A230463][L32253]
An additional 3-5% is eliminated in urine from 24 hours to 96 hours.
[A230463][L32253]
Biliary elimination has not been determined.
[A230463][L32253]
Carboplatin is predominantly eliminated as the unchanged parent compound.
[A230158][A230473]
[L32253]
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:11734551 PMID:16135512 PMID:17525160 PMID:19740744 PMID:20451502 PMID:20569931 PMID:23658018 PMID:26745413
May function in copper(1+) import from the apical membrane thus may drive intestinal copper absorption (By similarity). The copper(1+) transport mechanism is sodium-independent, saturable and of high-affinity .
PMID:11734551
Also mediates the uptake of silver(1+) .
PMID:20569931
May function in the influx of the platinum-containing chemotherapeutic agents .
PMID:20451502 PMID:20569931
The platinum-containing chemotherapeutic agents uptake is saturable (By similarity). In vitro, mediates the transport of cadmium(2+) into cells .
PMID:33294387
Also participates in the first step of copper(2+) acquisition by cells through a direct transfer of copper(2+) from copper(2+) carriers in blood, such as ALB to the N-terminal domain of SLC31A1, leading to copper(2+) reduction and probably followed by copper(1+) stabilization .
PMID:30489586
In addition, functions as a redox sensor to promote angiogenesis in endothelial cells, in a copper(1+) transport independent manner, by transmitting the VEGF-induced ROS signal through a sulfenylation at Cys-189 leadin g to a subsequent disulfide bond formation between SLC31A1 and KDR .
PMID:35027734
The SLC31A1-KDR complex is then co-internalized to early endosomes, driving a sustained VEGFR2 signaling PMID:35027734
PMID:17617060 PMID:17944601
Regulator of SLC31A1 which facilitates the cleavage of the SLC31A1 ecto-domain or which stabilizes the truncated form of SLC31A1 (Truncated CTR1 form), thereby drives the SLC31A1 truncated form-dependent endosomal copper export and modulates the copper and cisplatin accumulation via SLC31A1 (By similarity)
PMID:10419525 PMID:11092760 PMID:28389643
Within a catalytic cycle, acquires Cu(+) ion from donor protein on the cytoplasmic side of the membrane and delivers it to acceptor protein on the lumenal side. The transfer of Cu(+) ion across the membrane is coupled to ATP hydrolysis and is associated with a transient phosphorylation that shifts the pump conformation from inward-facing to outward-facing state .
PMID:10419525 PMID:19453293 PMID:19917612 PMID:28389643 PMID:31283225
Under physiological conditions, at low cytosolic copper concentration, it is localized at the trans-Golgi network (TGN) where it transfers Cu(+) ions to cuproenzymes of the secretory pathway .
PMID:11092760 PMID:28389643
Upon elevated cytosolic copper concentrations, it relocalizes to the plasma membrane where it is responsible for the export of excess Cu(+) ions .
PMID:10419525 PMID:28389643
May play a dual role in neuron function and survival by regulating cooper efflux and neuronal transmission at the synapse as well as by supplying Cu(+) ions to enzymes such as PAM, TYR and SOD3 (By similarity) .
PMID:28389643
In the melanosomes of pigmented cells, provides copper cofactor to TYR to form an active TYR holoenzyme for melanin biosynthesis (By similarity)
PMID:11306452 PMID:12958161 PMID:19506252 PMID:20705604 PMID:28554189 PMID:30405239 PMID:31003562
Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme .
PMID:20705604 PMID:23189181
Also mediates the efflux of sphingosine-1-P from cells .
PMID:20110355
Acts as a urate exporter functioning in both renal and extrarenal urate excretion .
PMID:19506252 PMID:20368174 PMID:22132962 PMID:31003562 PMID:36749388
In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates .
PMID:12682043 PMID:28554189 PMID:30405239
Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity).
Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux .
PMID:11306452 PMID:12477054 PMID:15670731 PMID:18056989 PMID:31254042
In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity).
In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response
PMID:10220572 PMID:10421658 PMID:11500505 PMID:16332456
Mediates hepatobiliary excretion of mono- and bis-glucuronidated bilirubin molecules and therefore play an important role in bilirubin detoxification .
PMID:10421658
Also mediates hepatobiliary excretion of others glucuronide conjugates such as 17beta-estradiol 17-glucosiduronic acid and leukotriene C4 .
PMID:11500505
Transports sulfated bile salt such as taurolithocholate sulfate .
PMID:16332456
Transports various anticancer drugs, such as anthracycline, vinca alkaloid and methotrexate and HIV-drugs such as protease inhibitors .
PMID:10220572 PMID:11500505 PMID:12441801
Confers resistance to several anti-cancer drugs including cisplatin, doxorubicin, epirubicin, methotrexate, etoposide and vincristine PMID:10220572 PMID:11500505
ATC L01XA02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Carboplatin
Additional database identifiers
Drugs Product Database (DPD)
1755
ChemSpider
8514637
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12805
GenAtlas
XDH
GeneCards
XDH
GenBank Gene Database
D11456
GenBank Protein Database
10336525
Guide to Pharmacology
2646
UniProt Accession
XDH_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7218
GenAtlas
MPO
GeneCards
MPO
GenBank Gene Database
J02694
GenBank Protein Database
189040
Guide to Pharmacology
2789
UniProt Accession
PERM_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4641
GenAtlas
GSTT1
GeneCards
GSTT1
GenBank Gene Database
X79389
GenBank Protein Database
510905
UniProt Accession
GSTT1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7393
GeneCards
MT1A
UniProt Accession
MT1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7406
GeneCards
MT2A
UniProt Accession
MT2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11179
GenAtlas
SOD1
GeneCards
SOD1
GenBank Gene Database
L44139
UniProt Accession
SODC_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4638
GenAtlas
GSTP1
GeneCards
GSTP1
GenBank Gene Database
M24485
GenBank Protein Database
31946
UniProt Accession
GSTP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4632
GenAtlas
GSTM1
GeneCards
GSTM1
GenBank Gene Database
X08020
GenBank Protein Database
31924
UniProt Accession
GSTM1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2874
GenAtlas
NQO1
GeneCards
NQO1
GenBank Gene Database
J03934
GenBank Protein Database
189246
UniProt Accession
NQO1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11016
GeneCards
SLC31A1
GenBank Gene Database
U83460
GenBank Protein Database
2315987
UniProt Accession
COPT1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11017
GeneCards
SLC31A2
GenBank Gene Database
U83461
GenBank Protein Database
2315989
UniProt Accession
COPT2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:869
GeneCards
ATP7A
GenBank Gene Database
L06133
GenBank Protein Database
179253
UniProt Accession
ATP7A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:870
GeneCards
ATP7B
GenBank Gene Database
U11700
GenBank Protein Database
551502
UniProt Accession
ATP7B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:74
GenAtlas
ABCG2
GeneCards
ABCG2
GenBank Gene Database
AF103796
GenBank Protein Database
4185796
Guide to Pharmacology
792
UniProt Accession
ABCG2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:53
GenAtlas
ABCC2
GeneCards
ABCC2
GenBank Gene Database
U63970
GenBank Protein Database
1764162
Guide to Pharmacology
780
UniProt Accession
MRP2_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
1 active patent
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: